Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia
Yi‐Bin Chen(Massachusetts General Hospital), Robert J. Soiffer(Dana-Farber Cancer Institute), Michelle A. Rudek(Dana-Farber Cancer Institute), Trivikram Rajkhowa(Dana-Farber Cancer Institute), Corey Cutler(Harvard University), Vincent T. Ho(Dana-Farber Cancer Institute), Thomas R. Spitzer(Harvard University), Sigitas Verselis(Dana-Farber Cancer Institute), Karen K. Ballen(University of Virginia Health System), Joseph H. Antin(Dana-Farber Cancer Institute), Christine Connolly(Massachusetts General Hospital), Andrew A. Lane(Dana-Farber Cancer Institute), Morgan Curtis(Massachusetts General Hospital), Candice Del Rio(Massachusetts General Hospital), Areej El‐Jawahri(Massachusetts General Hospital), Mark J. Levis(Sidney Kimmel Cancer Center), Betsy Valles(Massachusetts General Hospital), Shuli Li(Unknown), Steven L. McAfee(Harvard University), Amir T. Fathi(University of Southern California), Bimalangshu R. Dey(Harvard University), Amy Joyce(Dana-Farber Cancer Institute)
Cited by 234
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
HLA-Mismatched Renal Transplantation without Maintenance Immunosuppression
|New England Journal of Medicine|2008|972